organization · Reporting owner
Pontifax (Israel) III, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc.ELOX · Entity 7180 | 10% owner | May 20, 2020 | May 22, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eloxx Pharmaceuticals, Inc.
Report date May 20, 2020 · Filed May 22, 2020
Jointly reported with Pontifax Management 4 G.P. (2015) Ltd., Pontifax IV GP L.P., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax (Israel) IV, L.P., Pontifax Management III G.P. (2011) Ltd., Pontifax Management Fund III L.P., Pontifax (Cayman) III, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2030-05-20 | IndirectSee Footnote | 20,000 |
Reported balance
After 2020-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2: The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.39 · Expires 2030-05-20 | IndirectSee Footnote | 20,000 |
Reported balance
After 2020-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F3: The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
F2: The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
F3: The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2020 Filed May 22, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001415889-20-001306 · form4-05222020_040544.xml · derivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F3 · ownership.nature: The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001415889-20-001306 · form4-05222020_040544.xml · derivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 20, 2021 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.nature: The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax; and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
| May 29, 2019 Filed May 29, 2019 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-19-000624 · form4-05292019_020508.xml · derivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F3 · ownership.nature: The reported securities are owned by Ran Nussbaum, a director of Pontifax. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
| May 29, 2019 Filed May 29, 2019 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001415889-19-000624 · form4-05292019_020508.xml · derivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on May 29, 2020 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.nature: The reported securities are owned directly by Tomer Kariv, a director of Pontifax Management 4 G.P. (2015) Ltd. and Pontifax Management III G.P. (2011) Ltd. (collectively, "Pontifax"). Pontifax Management 4.G.P. (2015) Ltd., is the general partner of Pontifax Management 4 G.P. L.P., which is the general partner of each of Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P. and Pontifax (Israel) IV L.P. Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P., which is the general partner of each of Pontifax (Cayman) III L.P. and Pontifax (Israel) III L.P. Mr. Kariv will assign the economic interests of the reported securities to Pontifax and Pontifax may be deemed the indirect beneficial owner of the security. Pontifax disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:22 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.27 | $0.00 |
DisclosureSEC source: 0001209191-18-038661 · doc4.xml · derivative · entry 2 Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F3 · ownership.nature: The reported securities are owned directly by Ran Nussbaum, a general partner of Pontifax 3. Mr. Nussbaum will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 22:22 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $23.27 | $0.00 |
DisclosureSEC source: 0001209191-18-038661 · doc4.xml · derivative · entry 1 Pontifax Management III G.P. (2011) Ltd. · CIK 0001726335 · 10% owner Pontifax Management Fund III L.P. · CIK 0001726340 · 10% owner Pontifax (Cayman) III, L.P. · CIK 0001726028 · 10% owner Pontifax (Israel) III, L.P. · CIK 0001726038 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: One half (1/2) of the shares underlying the option shall vest on June 15, 2019 (the "Cliff Vesting Date"), the remainder of the grant shall vest in equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.nature: The reported securities are owned directly by Tomer Kariv, a general partner of Pontifax Management III G.P. (2011) Ltd. ("Pontifax 3"). Mr. Kariv will assign the economic interests of the reported securities to Pontifax 3 and it may be deemed the indirect beneficial owner of the security. Pontifax 3 disclaims beneficial ownership of the security except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.